Comparative Pharmacology
Head-to-head clinical analysis: ERYMAX versus ERYTHROMYCIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ERYMAX versus ERYTHROMYCIN.
ERYMAX vs ERYTHROMYCIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin acts by binding to the 50S subunit of the bacterial ribosome, inhibiting protein synthesis. It also acts as a motilin receptor agonist, stimulating gastrointestinal motility.
Binds to the 50S ribosomal subunit, inhibiting bacterial protein synthesis by blocking the translocation step.
250-500 mg orally every 6 hours or 500-1000 mg intravenously every 6 hours.
250-500 mg orally every 6 hours or 500-1000 mg intravenously every 6 hours; maximum 4 g/day.
None Documented
None Documented
Terminal elimination half-life: 1.5–2 hours in adults; prolonged to 4–6 hours in hepatic impairment; requires dosing adjustment in cirrhosis.
Clinical Note
moderateErythromycin + Norfloxacin
"Erythromycin may increase the QTc-prolonging activities of Norfloxacin."
Clinical Note
moderateErythromycin + Teriflunomide
"The serum concentration of Teriflunomide can be increased when it is combined with Erythromycin."
Clinical Note
moderateErythromycin + Ibandronate
"Erythromycin may increase the QTc-prolonging activities of Ibandronate."
Clinical Note
moderateErythromycin + Indapamide
Terminal half-life is 1.4-2 hours in adults with normal renal function; may be prolonged to 5-6 hours in anuria.
Renal excretion of unchanged drug: 10–15%; biliary/fecal excretion: 85–90% as active metabolites.
Primarily hepatic (biliary) elimination; approximately 2-5% excreted unchanged in urine, 30-60% excreted in feces via bile.
Category C
Category A/B
Macrolide Antibiotic
Macrolide Antibiotic
"Erythromycin may increase the QTc-prolonging activities of Indapamide."